#### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

#### **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	-	No
name, catalogue number and RRID, if available.		antibody
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	-	
Provide accession number in repository <b>OR</b>		No cell
supplier name, catalog number, clone number,		lines
OR RRID		
Primary cultures: Provide species, strain, sex of	-	N It
origin, genetic modification status.		No cultures
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	-	
genetic modification status. Provide accession		No
number in repository <b>OR</b> supplier name, catalog		animals
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the	-	
field: Provide species, sex and age where		No
possible		animals
Model organisms: Provide Accession number	-	
in repository (where relevant) <b>OR</b> RRID		No model
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	-	
number if available, and source (including location		No plants
for collected wild specimens)		
Microbes: provide species and strain, unique	-	
accession number if available, and source		No microbes
		microbes
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	This study was approved by the Ethic Committee at	-
equivalent committee(s), provide reference number	Qilu Hospital (reference number, KYLL-2021(KS)-013,	
for approval.	Methods/Tissue specimen provided)	
Provide statement confirming informed consent	Written informed consent was obtained from 3	-
obtained from study participants.	enrolled patients with ESCC undergoing the surgery in	
	the Department of Thoracic Surgery at Qilu Hospital	
	(Methods/Tissue specimens provided)	
Report on age and sex for all study participants.	56 years old / Male, 62 years old / Male and 64 years	-
	old / Male (Methods/Tissue specimens provided)	1

## Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.	-	No trials
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	-	No
by-step protocols are available.		protocol
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	-	No trial
done <b>, or</b> if they were not carried out.		design
Sample size determination	-	No
Randomisation	-	No
Blinding	-	No
Inclusion/exclusion criteria	-	No
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		No
replicated in laboratory		replicates
Define whether data describe technical or biological	-	No
replicates		replicates
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	This study was approved by the Ethic Committee at	-
authority granting ethics approval (IRB or equivalent	Qilu Hospital (reference number, KYLL-2021(KS)-013,	
committee(s), provide reference number for approval.	Methods/Tissue specimen provided)	
Studies involving experimental animals: State details	-	
of authority granting ethics approval (IRB or		No
equivalent committee(s), provide reference number for approval.		animals
Studies involving specimen and field samples: State if	This study was approved by the Ethic Committee at	-
relevant permits obtained, provide details of	Qilu Hospital (reference number, KYLL-2021(KS)-013).	
, , , , , , , , , , , , , , , , , , , ,		
authority approving study; if none were required,	Written informed consent was obtained from 3	
authority approving study; if none were required,	Written informed consent was obtained from 3 enrolled patients with ESCC undergoing the surgery in	
authority approving study; if none were required, explain why.		
authority approving study; if none were required,	enrolled patients with ESCC undergoing the surgery in	
authority approving study; if none were required, explain why.	enrolled patients with ESCC undergoing the surgery in the Department of Thoracic Surgery at Qilu Hospital (Methods/Tissue specimens provided)	n/a
authority approving study; if none were required, explain why. Dual Use Research of Concern (DURC)	enrolled patients with ESCC undergoing the surgery in the Department of Thoracic Surgery at Qilu Hospital	n/a No dual
authority approving study; if none were required, explain why.	enrolled patients with ESCC undergoing the surgery in the Department of Thoracic Surgery at Qilu Hospital (Methods/Tissue specimens provided)	

# <u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	-	No
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Methods/Statistical analysis provided	-
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	-	No
If data are publicly available, provide accession number in repository or DOI or URL.	-	No
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	-	No
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	-	No
State whether the code or software is available.	-	No
If code is publicly available, provide accession number in repository, or DOI or URL.	-	No

## **Reporting**

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/atm-21-4372